|Articles|September 1, 2013
- BioPharm International-09-01-2013
- Volume 26
- Issue 9
BioPharm International, September 2013 Issue (PDF)
Click the title above to open the BioPharm International September 2013 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 12 years ago
Trends in Downstream Bioprocessingover 12 years ago
Identification and Quantification of Trace-Level Protein Impuritiesover 12 years ago
Report from Brazilover 12 years ago
Regulatory Roundupover 12 years ago
Gauging the Outlook of the Biologics Marketover 12 years ago
The Elements of Trainingover 12 years ago
Prefilter Features PES Nanofleece Materialover 12 years ago
Ion Exchange Chromatography Resins for High-Resolution Purificationover 12 years ago
EU Raises API Standards: A Curse in Disguise?over 12 years ago
Best Practices for Restricted Access Barrier SystemsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
3
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
4
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
5
